Liposome as carrier therapy for Alzheimer’s disease

Main Article Content

Andi Sri Dewi Anggraeni
Emilia Vivi Arsita
Adika Suwarman


Alzheimer's disease (AD) is the most common type of dementia. Approximately 50 million people suffer from Alzheimer's and it is expected to increase more than 100 million by 2050. According to the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V), the diagnosis of AD has an onset of memory impairment and cognitive decline. Effective treatment of AD is a major challenge in the field of pharmacy and science due to the restriction from blood brain barrier (BBB). This causes poor access to pills or oral administration. Liposome as a part of nanoparticle showed to be a potential AD treatment because of its biocompatibility, flexibility, and capability to carry various therapeutic molecules across the BBB and into brain cells. Several types of liposomes provide varied therapy effect. Some factors which determine liposomes effectiveness are its structure, mechanism of action; formed; and delivery, and its preparation method. This article reviewed liposomes characteristics which has potency as carrier therapy for AD.


Article Details

How to Cite
Anggraeni, A. S. D., Arsita, E. V., Suwarman, A., & Mustofa. (2022). Liposome as carrier therapy for Alzheimer’s disease. Indonesian Journal of Pharmacology and Therapy, 3(2).
Author Biography

Mustofa, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Yogyakarta, Indonesia

Department of Pharmacology and Therapy


1. Altinoglu, G and Adal, T. 2020. Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems. Current Drug Targets, 21, 628-646.
2. Wong, K.H., Riaz, M.K., Xie, Y., Zhang, X., Liu, Q. 2019. Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier. Int. J. Mol. Sci 20, 381; doi:10.3390/ijms20020381.
3. Prabhakar, P., Banerjee, M. 2020. Nanotechnology in Drug Delivery System: Challenges and Opportunities.Nanotechnology in Drug Delivery System: Challenges and Opportunities. Pharm. Sci. & Res. Vol. 12(4), 2020, 492-498.
4. Ross, C., Taylor, M., Fullwood, N., Allsop, D. 2018. Liposome delivery systems for the treatment of Alzheimer’s disease. International Journal of Nanomedicine. 2018:13 8507–8522.
5. Kaul S, Gulati N, Verma D, Mukherjee S, Nagaich U. Role of Nanotechnology in Cosmeceuticals: A Review of Recent Advances. J Pharm (Cairo). 2018 Mar 27;2018:3420204. doi: 10.1155/2018/3420204. PMID: 29785318; PMCID: PMC5892223.
6. Li M, Du C, Guo N, Teng Y, Meng X, Sun H, Li S, Yu P, Galons H. Composition design and medical application of liposomes. Eur J Med Chem. 2019 Feb 15;164:640-653. doi: 10.1016/j.ejmech.2019.01.007. Epub 2019 Jan 7. PMID: 30640028.
7. Yadav, D., Sandeep, K., Pandey, D., Dutta, R.K. 2017. Liposomes for Drug Delivery. Journal Biotechnology Biomaterials. Vol (7):276. doi: 10.4172/2155-952X.1000276
8. Carita, A.C., Eloy, J.O., Chorill, M., Lee, R.J and Leonardi, G. R. 2018. Recent Advances and Perspectives in Liposomes for Cutaneous Drug Delivery. Current Medicinal Chemistry 25 (5): 606-635
9. Çagdas M, Sezer AD, Bucak S. 2014. Liposomes as potential drug carrier systems for drug delivery. Nanotechnol Nanomater 2014: 1-50.
10. Naeem, S., Viswanathan, G., Misran, M. B. 2017. Liposomes as colloidal nanovehicles: On the road to success in intravenous drug delivery. Rev Chem Eng 2017; aop. doi: DOI 10.1515/revce-2016-0018.
11. Patra, J. K., Das, K., Fraceto, L.F., Campos, E.V.R., Torres, M.P.R., Torres, L.S.A, et all. 2018. Nano based drug delivery systems: Recent Developments and Future Prospects. J Nanobiotechnol 16:71. 1-33.
12. Lee Y., Thompson D.H. 2018. Stimuli-Responsive Liposomes for Drug Delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 9(5):1-76. doi:10.1002/wnan.1450
13. Lila, A. S. A., Ishida. T. 2017. Liposomal Delivery Systems: Design Optimization and Current Applications. Biol Pharm Bull. Vol. 40(1):1-10.
14. Rajan, R., Jose, S., and Vasudevan, D. T. 2011. Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation. J Adv Technol Res 2 (3): 138-143.
15. Eloya, J.O., Petrilli, R., Trevizan, L.N.F., Chorilli, M. 2017. Immunoliposomes: A review on functionalization strategies and targets for drug delivery. Colloids and Surfaces B: Biointerfaces 159: 454–467
16. Chavda, V. P. 2016. Escheriosome: Apotential antigen carrier. JIAPS 1(1): 15-20
17. Al-kaf, A.G.A and Othman, A. M. 2017. A Review On Pharmacosomes: An Emerging Novel Vesicular Drug Delivery System. Universal Journal of Pharmaceutical Research 2 (1): 21-24.
18. Zahid, S. R., Upmanyu, Y., Dangi, S., Ray, S. K., Jain, P., and Parkhe, G. 2018. Ethosome: a novel vesicular carrier for transdermal drug delivery
19. El-Sayed, A., Kamel, M. 2020. Advanced applications of nanotechnology in veterinary medicine. Environmental Science and Pollution Research. 27:19073–19086. doi:
20. Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. Recent advances in "smart" delivery systems for extended drug release in cancer therapy. Int J Nanomedicine. 2018 Aug 20;13:4727-4745. doi: 10.2147/IJN.S168053. PMID: 30154657; PMCID: PMC6108334.
21. Blair, H. A. 2018. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. 78:1903–1910. doi:
22. Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I. et al. Nanomedicine review: clinical developments in liposomal applications. Cancer Nano 10, 11 (2019).